Moderna (Contract Mfg) vs ReciBioPharm: CDMO Comparison

Side-by-side comparison of Moderna (Contract Mfg) and ReciBioPharm on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Norwood, MA
Signal Score
82/100
Quality (FDA + GMP)
100/100
FDA inspections
2
— NAI / VAI / OAI
2 / 0 / 0
FDA warning letters
0
EMA GMP certificates (active)
3
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
10
Capacity
Modalities
mRNA
Keele, UK · Sodertalje, SE
Signal Score
88/100
Quality (FDA + GMP)
100/100
FDA inspections
0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
3
Clinical programs (matched)
0
Capacity
Modalities
AAV, Lentiviral, Plasmid, mRNA

Key differences

  • Moderna (Contract Mfg) has FDA inspections on record (2); ReciBioPharm does not yet appear in the FDA inspection database.
  • Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
  • Moderna (Contract Mfg) holds 3 active EMA GMP certificates; ReciBioPharm does not appear in EudraGMDP.
  • ReciBioPharm maintains 3 MHRA / UK GMP certificates; Moderna (Contract Mfg) does not.
  • Moderna (Contract Mfg) appears as a manufacturing partner on more matched clinical programs (10 vs 0) — a broader sponsor book.

On a 13-modality CDMO landscape, both Moderna (Contract Mfg) and ReciBioPharm qualify as mRNA/LNP manufacturers; ReciBioPharm carries the higher composite Signal Score for mRNA/LNP programs in this comparison.

What to evaluate for mRNA/LNP programs

Both Moderna (Contract Mfg) and ReciBioPharm qualify as mRNA/LNP CDMOs. When choosing between them for mRNA/LNP programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.

IVT mRNA synthesis

Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost.

LNP formulation

LNP encapsulation via microfluidics determines potency and tolerability. Confirm lipid sourcing, formulation freedom-to-operate, and particle-size control.

Plasmid / starting material

mRNA needs a DNA template. Check whether the CDMO supplies GMP plasmid in-house or coordinates a plasmid CDMO — it affects timelines.

Cold chain & stability

mRNA-LNP products are temperature-sensitive. Evaluate frozen storage, fill-finish, and the stability program.

See all mRNA/LNP CDMOs ranked by Signal Score →

Frequently asked: Moderna (Contract Mfg) vs ReciBioPharm

Which has the stronger FDA inspection record, Moderna (Contract Mfg) or ReciBioPharm?

Both Moderna (Contract Mfg) and ReciBioPharm maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Moderna (Contract Mfg) has 2 FDA inspections on record; ReciBioPharm has 0.

How do Moderna (Contract Mfg) and ReciBioPharm compare on European GMP coverage?

Moderna (Contract Mfg) holds 3 active EMA GMP certificates and 0 MHRA / UK certificates. ReciBioPharm holds 0 active EMA GMP certificates and 3 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

Which is more active in clinical-stage manufacturing — Moderna (Contract Mfg) or ReciBioPharm?

Moderna (Contract Mfg) is matched to 10 ClinicalTrials.gov records as a manufacturing partner; ReciBioPharm is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.

Which is better for mRNA/LNP manufacturing — Moderna (Contract Mfg) or ReciBioPharm?

Both Moderna (Contract Mfg) and ReciBioPharm are tagged as mRNA/LNP CDMOs in our directory, so both are credible options for mRNA/LNP programs. The most important differentiator for mRNA/LNP selection is typically ivt mrna synthesis: Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost. Review each CDMO's profile and inspection record before shortlisting.

What does the Signal Score gap mean in practice?

Moderna (Contract Mfg) carries a Signal Score of 82/100 and ReciBioPharm carries 88/100 — a small lead for ReciBioPharm. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating Moderna (Contract Mfg) and ReciBioPharm for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.